Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
Aqualung Therapeutics (Aqualung Therapeutics Corporation) leadership are experienced academic leaders, entrepreneurs and translational scientists with expertise in Precision Medicine, who are exploring NAMPT as a key target and novel diagnostic in acute and chronic lung inflammatory disorders. As an organization they are committed to finding novel targets in the treatment of respiratory diseases. Their team is highly skilled at clinical development and they are working collaboratively with the FDA to ensure both acute and chronic respiratory diseases that have significant unmet medical need receive priority review.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 22, 2020 | Grant | $300K | 1 | National Institutes of Health | — | Detail |
Jun 2, 2020 | Grant | $2.30M | 1 | National Institutes of Health | — | Detail |
Aug 20, 2019 | Grant | $225K | 1 | National Institutes of Health | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |